Key Features of Klebsiella pneumoniae Pathogenicity

Klebsiella pneumoniae succeeds as a pathogen because it layers multiple defenses and attack strategies on top of one another, creating redundancy that makes it exceptionally hard for the immune system and antibiotics to eliminate. Its thick polysaccharide capsule, ability to scavenge iron in nutrient-starved tissue, talent for hiding inside immune cells, and capacity to form stubborn biofilms all contribute to infections that range from hospital-acquired urinary tract infections to devastating liver abscesses in otherwise healthy people. What makes the current moment especially worrying is that strains historically known for extreme virulence and strains known for extreme drug resistance, once found in separate parts of the world, are now merging into single organisms that carry the worst features of both.

The Capsule as a Molecular Shield

If you had to pick one feature that defines K. pneumoniae pathogenicity, it would be the capsular polysaccharide, or CPS. This thick sugar coat surrounds the bacterium and physically blocks the host’s first-line immune defenders from latching on. Experiments show that CPS prevents a receptor on immune cells called LOX-1 from binding to the bacterium, which reduces phagocytosis, the process by which immune cells engulf and destroy invaders.¹ The capsule also resists antimicrobial peptides and blocks complement proteins from depositing on the bacterial surface, two key immune killing mechanisms.²

Not all capsule types are equally dangerous. Among the roughly 80 recognized capsule serotypes, K1 and K2 stand out. Strains carrying these capsule types are the most effective at avoiding clearance by Kupffer cells, the resident immune cells of the liver, and are responsible for the majority of Klebsiella liver abscess cases.³ This capsule-type specificity explains why certain strains cause severe invasive disease while most K. pneumoniae in the environment remain relatively harmless gut commensals.

Hypermucoviscosity Beyond the Capsule

Closely related to the capsule, but functionally distinct, is hypermucoviscosity. Hypervirulent K. pneumoniae strains often produce an exaggerated slimy coating detectable by the “string test,” where a bacterial colony can be stretched into a viscous string several centimeters long. For years, researchers assumed hypermucoviscosity was simply a consequence of extra capsule production. That turns out to be wrong. Mutant strains that lose the regulator gene rmpA have reduced capsule and lose hypermucoviscosity, but the two traits can be uncoupled: strains can retain hypermucoviscosity even with reduced capsule expression.⁴

This distinction matters because hypermucoviscosity has its own independent effect on pathogenicity. When bacteria acquire a plasmid carrying rmpA or its relative rmpA2, they overproduce hypermucoviscous material. This overproduction, rather than extra capsule itself, is what reduces binding to human cells and increases the bacterium’s survival when exposed to neutrophils.⁵ In practical terms, hypermucoviscosity gives the bacterium a second, independent way to dodge the immune system, so even if the capsule is partially degraded, the slimy coat still provides protection.

Scavenging Iron in Host Tissue

Iron is essential for bacterial growth, and the human body deliberately locks it away inside proteins to starve pathogens of this critical nutrient. K. pneumoniae fights back with siderophores, small molecules that steal iron from host proteins. Most strains produce at least one siderophore called enterobactin, but hypervirulent strains go further by producing aerobactin, a siderophore that has been shown to play a central role in mediating their enhanced virulence.⁶ Siderophores, the ability to metabolize allantoin (a nitrogen-rich compound found in human tissue), and the iron uptake system encoded by genes like iucABCD and iutA together form a metabolic toolkit that allows hypervirulent strains to thrive in environments where ordinary strains starve.⁷

Allantoin metabolism itself is strikingly associated with liver abscess strains. A chromosomal region encoding allantoin-processing genes was found far more frequently in K. pneumoniae strains isolated from liver abscesses than in non-abscess strains, and deleting a key gene in this region significantly reduced virulence in animal models.⁸

The O-Antigen and Complement Resistance

Beyond the capsule, K. pneumoniae has another sugar-based defense embedded in its outer membrane: the O-antigen portion of lipopolysaccharide (LPS). Classic work established that resistance to the bactericidal activity of complement, the blood’s main system for killing bacteria, is driven largely by these O-antigen chains.⁹ More recent work has clarified the mechanism: the O1-antigen, the most common O-antigen type in clinical isolates, does not stop the early steps of complement activation. It actually allows more complement components to deposit on the bacterial surface. The trick happens at the very last step, where the O1-antigen prevents the final complement protein, C9, from properly inserting into the bacterial membrane and forming the pores that would kill the cell.¹⁰

This is a counterintuitive defense strategy. Instead of hiding from complement, the bacterium tolerates the early stages and sabotages only the killing blow. The result is that even though complement proteins pile up on the surface, they cannot form functional pores, and the bacterium survives in the bloodstream.

Fimbriae and Biofilm Formation

To establish an infection, K. pneumoniae has to stick to something, whether that is bladder tissue, lung epithelium, or the plastic surface of a catheter. It uses hair-like projections called fimbriae for this purpose. Two types dominate: type 1 fimbriae, which bind to mannose-containing receptors on human cells, and type 3 fimbriae, which are especially good at adhering to abiotic surfaces like medical devices. In catheter-associated urinary tract infections, both types enhance biofilm formation and can compensate for each other; if one is disabled, the other picks up the slack.¹¹ Mouse models confirm that both fimbrial types enhance colonization and persistence on implanted silicone tubes, and strains lacking both are significantly outcompeted by wild-type bacteria.¹²

Once attached, K. pneumoniae builds biofilms, structured communities encased in a self-produced matrix. Biofilms are a critical obstacle in treatment because they dramatically increase antibiotic resistance.¹³ Bacteria deep inside a biofilm can tolerate antibiotic concentrations hundreds of times higher than free-floating cells of the same strain, which helps explain why device-related K. pneumoniae infections are so difficult to clear without removing the hardware.

Surviving Inside the Cells Meant to Kill It

One of the more surprising discoveries about K. pneumoniae is that it can survive inside macrophages, the very immune cells tasked with eating and destroying bacteria. After being engulfed, K. pneumoniae resides in a specialized compartment called the Klebsiella-containing vacuole, which avoids fusing with lysosomes, the cell’s digestive compartments.¹⁴ The bacterium achieves this by hijacking a signaling pathway involving the molecules PI3K, Akt, and Rab14, a strategy shared with other famous intracellular pathogens like Salmonella and Mycobacterium tuberculosis.¹⁵

Inside the macrophage, K. pneumoniae even reprograms the host cell’s behavior, pushing it toward a distinct polarization state that favors bacterial survival. This intracellular niche gives the bacterium a protected base from which it can persist in tissue while remaining hidden from circulating antibiotics and antibodies. It also eventually triggers the macrophage to undergo a form of programmed cell death, potentially releasing bacteria to start the cycle over.

Outer Membrane Vesicles as Remote Weapons

K. pneumoniae does not limit its influence to direct contact. It sheds small bubble-like structures called outer membrane vesicles (OMVs) that carry virulence factors and can travel to distant host cells.¹⁶ Hypervirulent strains produce OMVs loaded with diverse proteins that provoke strong inflammatory responses. When injected into the airways of mice, these vesicles alone, without any live bacteria, trigger elevated levels of inflammatory molecules in the lungs.¹⁷ This means the bacterium can cause tissue damage and redirect immune resources at a distance, softening up the environment for further invasion.

Outcompeting Other Bacteria

Pathogenicity is not just about evading the immune system. K. pneumoniae also has to compete with trillions of other microbes in the gut and at infection sites. It deploys a type VI secretion system, a molecular syringe that injects toxic proteins directly into neighboring bacterial cells, killing competitors and carving out ecological space.¹⁸ This system is especially relevant in the gut, where K. pneumoniae needs to establish sufficient density before it can breach the intestinal barrier and seed distant organ infections.

Liver Abscesses and Metastatic Spread

The clinical hallmark of hypervirulent K. pneumoniae is pyogenic liver abscess. In this syndrome, the bacterium colonizes the gut, crosses the intestinal barrier, and reaches the liver via the portal vein. Once there, K1 and K2 capsule-bearing strains resist clearance by Kupffer cells and form walled-off pockets of infection that are extremely difficult to treat.³ Antibiotics penetrate poorly into abscess cavities, often requiring drainage procedures or even surgical removal of liver tissue.

What makes these infections especially alarming is metastatic spread. The bacterium can disseminate from the liver to the eyes, brain, lungs, and other organs. Endophthalmitis, an infection inside the eye, is one of the most feared complications and can lead to permanent vision loss or death even with aggressive treatment.¹⁹ This invasive syndrome was first described predominantly in East Asia but has been reported on every inhabited continent.

When Hypervirulence Meets Drug Resistance

Historically, the K. pneumoniae strains causing liver abscesses (hypervirulent strains, often sequence types like ST23, ST65, and ST86, mostly found in East and Southeast Asia) and the strains causing hard-to-treat hospital infections due to drug resistance (multidrug-resistant strains like ST258, ST147, ST101, common in healthcare settings worldwide) were separate populations.²⁰ The boundaries between these two pathotypes are dissolving.

Laboratory studies have demonstrated that the virulence plasmid from hypervirulent strains can be transferred into carbapenem-resistant K. pneumoniae backgrounds through several mechanisms, including co-transfer with conjugative plasmids or formation of hybrid plasmids through recombination.²¹ This is not theoretical. A clinical isolate recovered in the United States in 2017 was ST11 and carried two plasmids: one with the carbapenemase gene blaKPC-2, and another carrying both the metallo-β-lactamase gene blaNDM-1 and hypervirulence genes including iucABCD, rmpA, and rmpA2.²² Such convergent strains resist nearly all available antibiotics while retaining the ability to cause severe invasive disease in healthy individuals.

Colistin Resistance and the Erosion of Last-Resort Options

When carbapenem antibiotics fail, clinicians often turn to colistin (polymyxin E), an older drug with significant side effects that serves as a treatment of last resort. K. pneumoniae can develop resistance to colistin through acquisition of the mcr-1 gene, which modifies the lipid A portion of LPS and disrupts the way colistin binds to the bacterial surface.²³ Because mcr-1 is plasmid-borne, it can spread horizontally between strains and species, raising the prospect of pan-resistant K. pneumoniae infections for which no conventional antibiotic works.

Who Faces the Greatest Risk

While hypervirulent strains famously strike otherwise healthy adults, host factors still matter. People with diabetes face increased susceptibility to carbapenem-resistant hypervirulent K. pneumoniae in part because their neutrophil extracellular traps (NETs), web-like structures that neutrophils release to catch and kill bacteria, are less effective. In laboratory experiments, over 70% of bacteria survived exposure to NETs from people with type 2 diabetes, while fewer than 20% survived NETs from healthy controls.²⁴ The impaired killing was associated with reduced physical damage to the bacterial surface, suggesting that diabetic NETs simply fail to tear the bacteria apart as efficiently.

Environmental Reservoirs and One Health Concerns

K. pneumoniae is not confined to hospitals. Drug-resistant, virulence-gene-carrying strains have been recovered from municipal wastewater and poultry farms, and phylogenetic analysis shows that isolates from these agricultural and wastewater settings are clonally related to each other and share the same virulence genes found in clinical strains.²⁵ Wastewater treatment plants have been identified as critical environmental reservoirs for colistin-resistant K. pneumoniae strains carrying mcr-1, with potential transmission routes to both humans and aquatic ecosystems.²⁶ This environmental dimension means that controlling K. pneumoniae is not just a hospital infection-control problem; it requires monitoring across the food chain and water systems.

Phage-Derived Therapies Targeting the Capsule

Given how central the capsule is to K. pneumoniae pathogenicity, researchers are exploring enzymes derived from bacteriophages (viruses that infect bacteria) that specifically strip away capsular polysaccharides. These phage-derived depolymerases work like molecular scissors, cutting the sugar chains that form the capsule and leaving the bacterium exposed to the immune system. One such enzyme, P560dep, targets the KL47 capsule type common among carbapenem-resistant strains. In mouse models, a single dose protected 90 to 100% of mice from lethal infection, and it significantly inhibited biofilm formation.²⁷

Similar results have been seen with depolymerases targeting other capsule types. An enzyme called PRA33gp45 degrades K27 capsules, disrupts mature biofilms, reduces bacterial survival inside human lung cells, and sensitizes bacteria to complement killing in human serum.²⁸ Depolymerases also have a practical advantage over whole phages: they work even against bacterial strains that resist phage infection. In a direct comparison against K2-type K. pneumoniae, a purified depolymerase was effective against strains that did not support the parent phage’s replication, while the phage alone was completely inactive against those strains.²⁹

The major limitation is specificity: each depolymerase typically targets only one or a few capsule types, and K. pneumoniae has dozens. A realistic therapeutic strategy would likely require cocktails of multiple depolymerases or use them as adjuncts alongside conventional antibiotics to strip the capsule and let existing drugs finish the job. Researchers are also investigating whether capsule-targeted antibodies could serve a similar function; early work shows that serotype-specific antibodies can promote complement-mediated killing in laboratory assays, though cross-reactivity between serotypes is minimal, reinforcing the challenge of capsular diversity.³⁰